5 completed, 2 recruiting, 1 active not recruiting, 1 not yet recruiting. 4 Phase 3, 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 4 |
| Phase 4 | 2 | Not yet recruiting 1, Recruiting 1 |
Follow Atogepant 60 mg: new trials by email Literature Review of Atogepant 60 mg trials Research Report on Atogepant 60 mg
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Atogepant on the Vestibulo-Ocular Reflex in Healthy Adults and Adults With Migraine Atogepant 60 mg, Placebo - Migraine Disorders, Brain, Healthy Adult Participants | Phase 4 | Not yet recruiting | Konrad Peter Weber | 80 | 2027-01-01 | 2026-09-17 |
| Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study Atogepant 60 mg, Propranolol 160 mg, Topiramate 100 mg - Migraine | Phase 4 | Recruiting | Mayo Clinic | 1335 | 2025-07-09 | 2026-10-19 |
| Neurophysiological and Biomolecular Effects of Atogepant in Episodic Migraine Atogepant 60 mg - Migraine Disorder, Episodic Migraine | Recruiting | IRCCS National Neurological Institute "C. Mondino" Foundation | 30 | 2024-12-01 | 2025-03-18 | |
| Long-term Atogepant in Real-world Practice Atogepant 60 mg, Headache diary, Patient-reported outcome measures - Migraine, Headache | Completed | Fundación de Investigación Biomédica - Hospital Universitario de La Princesa | 513 | 2024-06-01 | 2026-09-23 | |
| Italian Real-life obServational Study on the effecTiveness, sAfety and Tolerability of Atogepant in Migraine Patients Atogepant 60 mg - Migraine, Migraine With Aura | Active not recruiting | University of Florence | 500 | 2024-05-09 | 2026-01-21 | |
| Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments. Atogepant 60 mg, Placebo - Episodic Migraine | Phase 3 | Completed | Allergan | 315 | 2021-03-05 | 2023-09-21 |
| A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine Atogepant 60 mg - Episodic Migraine, Chronic Migraine | Phase 3 | Completed | AbbVie | 596 | 2021-02-19 | 2025-12-18 |
| A Study Evaluating Oral Atogepant for the Prevention of Migraine in Japanese Participants With Chronic or Episodic Migraine Atogepant 60 mg - Chronic Migraine, Episodic Migraine | Phase 3 | Completed | AbbVie | 186 | 2020-06-18 | 2025-07-22 |
| Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine Atogepant 30 mg, Atogepant 60 mg, Placebo - Chronic Migraine | Phase 3 | Completed | Allergan | 778 | 2019-03-11 | 2023-02-14 |
Migraine Disorders (5) · Headache (2) · Migraine with Aura (2) · Headache Disorders, Secondary (1) · Migraine without Aura (1) · Pain (1) · Prescription Drug Overuse (1)
AbbVie (2) · Allergan (2) · Fundación de Investigación Biomédica - Hospital Universitario de La Princesa (1) · IRCCS National Neurological Institute "C. Mondino" Foundation (1) · Konrad Peter Weber (1) · Mayo Clinic (1) · University of Florence (1)
Italy (5) · Spain (4) · United States (4) · Canada (3) · Czechia (3) · Denmark (3) · France (3) · Germany (3) · Poland (3) · United Kingdom (3) · Australia (2) · Hungary (2) · Japan (2) · Netherlands (2) · Russia (2)
Ana Beatriz Gago Veiga (1) · Konrad P Weber, Prof. (1) · Todd J Schwedt, M.D. (1)
PMID 39648617, PMID 39715475, PMID 39982105, PMID 33142014, PMID 33942560, PMID 37516125, PMID 38364831, PMID 38924724, PMID 39648629, PMID 40267275, PMID 40471213, PMID 40831083, PMID 41222899, PMID 41814051, PMID 41878762, PMID 42360082
2018 (1), 2019 (1)